Document › Details
Evolva Holding S.A.. (2/26/14). "Presss Release: Evolva Successfully Places New Shares".
|Organisation||Evolva Holding S.A.|
|Organisation 2||Credit Suisse (Group)|
|Today||Credit Suisse Group AG|
|Product 2||investment banking|
|Index term||Evolva–SEVERAL: investment, 201402–201403 private placement CHF42.5m with 27m+5.5m new shares CHF1.37/share|
|Person||Goldsmith, Neil (Evolva 200910 CEO)|
Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) has successfully completed its placement of shares which was announced yesterday. Evolva has sold 27,000,000 new shares via an accelerated bookbuild process by way of a private placement in Switzerland and outside of Switzerland in accordance with applicable securities laws. The shares have been placed at a price of CHF 1.37 per share, representing a discount of 4.9% to the closing price of 25 February 2014.
The placement results in gross proceeds for the Company of CHF 37 million. Evolva’s outstanding number of shares will increase by 27,000,000 shares, from 248,780,937 shares (this number includes 6 million treasury shares currently being created in connection with the Company’s Standby Equity Distribution Agreement (SEDA)) to 275,780,937 shares. Evolva will use the proceeds from the share placement to increase the Company’s investment and upside in existing and future projects.
In addition, the Company has granted Credit Suisse, who is acting as Sole Bookrunner in the private placement, an over-allotment option of up to 4,050,000 additional shares which can be exercised within 30 days after the first trading day of the new shares on SIX Swiss Exchange. The shares underlying the over-allotment option will be sourced from the 6 million new treasury shares.
Neil Goldsmith, Evolva’s CEO, commented “We are very grateful for the strong interest from new and existing investors. It provides us with financial muscle to accelerate progress and increase the upside for our shareholders. The strong demand from investors is a sign of confidence in Evolva’s technology and business model.”
Trading in the new shares on SIX Swiss Exchange is expected to commence on 27 February 2014 and the settlement of the new shares is expected to take place on 3 March 2014. The 6 million new treasury shares are also expected to be listed on SIX Swiss Exchange on 27 February 2014.
The Company has agreed that no additional shares will be issued or sold without the consent of Credit Suisse for a period of 180 days which started on 25 February 2014.
– Ends –
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com.
Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
firstname.lastname@example.org email@example.com firstname.lastname@example.org
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035
Cautionary Statement About Preliminary Unaudited Financial Results, Business Update and Other Forward-looking Statements
All figures of the preliminary, unaudited financial results for 2013 contained in this press release are preliminary and reflect Evolva’s expected 2013 financial results based on financial information available as of the date of this press release. Actual reported 2013 financial results could differ materially from those contained in this press release because of a number of factors, including additional or revised information, subsequent events that may affect the fair value of assets at 31 December 2013, and changes in accounting standards or policies or in how those standards are applied. Evolva will provide additional discussion and analysis and other important information about its 2013 financial results and condition when it reports actual results on 8 April 2014.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. This press release has been prepared solely for purposes of complying with the ad-hoc disclosure rules of SIX Swiss Exchange and is for information only. It does not constitute an offer or invitation to sell, or a solicitation of an offer to buy shares in Evolva Holding SA (the “Shares”) in any jurisdiction, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefore. The Shares will solely be sold by way of a private placement to selected qualified investors who do not purchase the Shares with the intention to distribute them to the public and without any public advertisement.
This press release does not constitute (i) an offering prospectus, and no securities will be offered directly or indirectly to the public, within the meaning of Art. 652a of the Swiss Code of Obligations, (ii) a listing prospectus within the meaning of the SIX Swiss Exchange Listing Rules, nor (iii) a prospectus within the meaning of the EC Directive 2003/71/EC of the European Parliament and of the Council dated November 4, 2003 (the “Prospectus Directive”).
This press release is only addressed to, and is only directed at, qualified investors in any member state of the European Economic Area within the meaning of the Prospectus Directive (“Qualified Investors”).
The Shares that are the subject of the placement are not being offered or sold to any person in the United Kingdom, other than to qualified investors as defined in Section 86(7) of the Financial Services and Markets Act 2000, being persons falling within Article 2.1(E)(i), (ii) or (iii) of Directive 2003/71/EC of the European Parliament and of the Council dated 4 November 2003 (Prospectus Directive), which includes legal entities which are regulated by the Financial Services Authority and entities which are not so regulated whose corporate purpose is solely to invest in securities and who also fall within the definition of “Investment Professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (the “FPO”) and high net worth entities falling within Article 49(2)(a) to (d) of the FPO.
IN ADDITION, THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN AND ARE NOT INTENDED TO BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THAT ACT OR AN AVAILABLE EXEMPTION FROM REGISTRATION REQUIREMENTS UNDER THAT ACT.
In connection with the private placement of the Shares, Credit Suisse AG will be acting as stabilisation manager (the “Stabilisation Manager”) and may undertake measures aiming at supporting the stock exchange price or market price of the Shares for a predetermined period of time due to selling pressure in those securities (the “Stabilisation”). The Stabilisation Manager is under no obligation to engage in any Stabilisation and, accordingly, there is no assurance that Stabilisation will be undertaken. If Stabilisation is undertaken, it may be discontinued at any time without prior notice. Stabilisation may be carried out as from the date the final placement price of the Shares is adequately publicly disclosed and will end no later than 30 calendar days after the first trading day of the new Shares on SIX Swiss Exchange. As a result of such Stabilisation measures, the market price of the Shares may be higher than would otherwise prevail in the market. Stabilisation may also result in a market price at a level that is not sustainable in the long-term. Any Stabilisation will be carried out in accordance with art. 55 e of the Swiss Federal Ordinance on Stock Exchanges and Securities Trading (SESTO) and will not be conducted at a price exceeding the price at which the Shares are sold in the private placement. Save as required by law or regulation, neither Credit Suisse AG nor any of its agents intends to disclose the extent of any over-allotments made and/or Stabilisation transactions conducted in relation to the private placement.
Credit Suisse AG is acting as Sole Bookrunner for Evolva Holding SA in connection with the private placement and for no-one else and will not be responsible to anyone other than Evolva Holding SA for providing the protections afforded to its clients nor for providing advice in relation to the private placement or any other matter referred to herein.
Record changed: 2016-06-07
More documents for Evolva (Group)
-  Evolva Holding S.A.. (11/29/16). "Press Release: Evolva Appoints Oliver Walker as CFO. Strong Track Record as CFO of Nobel Biocare, Sonova and Stratec"....
-  Acesion Pharma ApS. (11/15/16). "Press Release: Acesion Pharma Recruits an Experienced Life Science Chief Financial Officer". Copenhagen....
-  Evolva Holding S.A.. (10/27/16). "Press Release: ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications". Dublin & Reinach....
-  Evolva Holding S.A.. (8/18/16). "Press Release: Evolva Publishes Financial Results for the First Half of 2016 and Provides Business Update"....
-  Evolva Holding S.A.. (8/17/16). "Press Release: Evolva Enters Partnership on Active Pharmaceutical Ingredients. Partner to Fully Fund Development of New Production Routes for a Family of APIs"....
-  Evolva Holding S.A.. (8/10/16). "Press Release: Evolva’s Collaboration with US Navy to Focus on Resveratrol-based Composites"....
-  Evolva Holding S.A.. (8/4/16). "Press Release: Evolva Establishes Sales Office in Singapore"....
-  Evolva Holding S.A.. (4/13/16). "Press Release: Evolva Proposes Gerard Hoetmer as New Board Member"....
-  Evolva Holding S.A.. (4/11/16). "Press Release: Evolva to Co-develop Next-generation Materials with US Navy"....
-  Evolva Holding S.A.. (4/5/16). "Press Release: Evolva Gains Exclusive License to Develop and Commercialise Nootkatone Globally for Pest Control"....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)